The epidermal growth factor receptor (EGFR) is a tyrosine kinase receptor that plays a crucial role in cell differentiation and tumor progression, and its overexpression is closely associated with the development and metastasis of multiple cancers. The development of a fluorescent probe capable of targeting EGFR while simultaneously integrating diagnostic and therapeutic functions could have a profound impact on the treatment of related cancers. In this study, we developed a series of EGFR-targeting probes that consisted of an environment-sensitive 1,8-naphthalimide fluorophore, a linker unit and a targeting unit (gefitinib), using a coupling strategy. The synthesized probes were first evaluated for their spectroscopic properties and cytotoxicities against different cell lines, which were selected based on their intrinsic EGFR expression levels. Remarkably, among the probes tested, GP1 showed outstanding environmental sensitivity and exhibited a specific response to tumor cells that overexpress EGFR. Furthermore, the representative probe GP1 was evaluated for its EGFR-specific targeting ability in live-cell fluorescence imaging and xenograft imaging, as well as its anti-tumor activity. The results showed that the probe GP1 had excellent EGFR-specific targeting ability, exhibited competitive replacement behavior towards the EGFR inhibitor gefitinib, and demonstrated potent anti-tumor effects in a CT-26 tumor-bearing mouse model. Overall, as a turn-on EGFR targeting fluorescent ligand, GP1 holds immense promise as a valuable tool for tumor detection and treatment.

Download full-text PDF

Source
http://dx.doi.org/10.1039/d3an01675gDOI Listing

Publication Analysis

Top Keywords

targeting egfr
8
tumor detection
8
detection treatment
8
probe gp1
8
egfr-specific targeting
8
targeting ability
8
egfr
7
targeting
6
design synthesis
4
synthesis biological
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!